key: cord-0790752-94x96kd5 authors: Yekedüz, Emre; Utkan, Güngör; Ürün, Yüksel title: A Systematic Review and Meta-Analysis: The Effect of Active Cancer Treatment on Severity of COVID-19 date: 2020-10-06 journal: Eur J Cancer DOI: 10.1016/j.ejca.2020.09.028 sha: 80135fec462cabd13862d123d2e8f770203a065c doc_id: 790752 cord_uid: 94x96kd5 BACKGROUND: The COVID-19 pandemic hit all over the world and cancer patients are more vulnerable for COVID-19. Mortality rate may increase up to 25% in solid malignancies. In parallel to increased mortality rates among cancer patients, safety concerns regarding cancer treatment has increased over time. However, there were contradictory results for the cancer treatment during pandemic. In this study, we assessed the effect of cancer treatment on the severity of COVID-19. METHODS: The MEDLINE database was searched on September 01, 2020. Primary endpoints were severe disease and death in the cancer patients treated within the last 30 days before COVID-19 diagnosis. Quality of included studies were assessed by New Castle-Ottawa Scale. Generic inverse variance method was used to calculate odds ratios (ORs) for each outcome. RESULTS: Sixteen studies were included for this meta-analysis. Chemotherapy within the last thirty days before COVID-19 diagnosis increased the risk of death in cancer patients after adjusting for confounding variables (OR: 1.85; 95% CI:1.26-2.71). However, severe COVID-19 risk did not increase. Furthermore, targeted therapies, immunotherapy, surgery, and radiotherapy did not increase the severe disease and death risk in cancer patients with COVID-19. CONCLUSION: Chemotherapy increased the risk of death from COVID-19 in cancer patients. However, there was no safety concern for immunotherapy, targeted therapies, surgery, and radiotherapy. After reporting the first case of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2) infection in Wuhan, China, coronavirus disease 2019 (COVID-19) became a pandemic in a short time and hit all over the world. As of September 13, 2020, 28,584,158 confirmed cases and 916,955 death from COVID-19 were observed across the world. 1 Cancer patients are more vulnerable for COVID-19. The case fatality rate was 25% for solid organ malignancies; however, it is 2.3% for the general population. 2, 3 In this context, since the beginning of the pandemic, there have been some concerns regarding cancer patients' treatment. We observe that the decision-making processes of oncologists are affected globally during the COVID-19 pandemic. 4 However, the European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) recommended continuing cancer treatment by evaluate and discuss the risk and benefit of cancer treatment with each individual. 5, 6 Despite no clear evidence for the safety of using chemotherapy (CT), immunotherapy, targeted therapies, radiotherapy (RT), and performing surgery in the cancer patients during the COVID-19 pandemic, cancer patients treated in the light of these recommendations. Over time, the knowledge about cancer treatment in the pandemic increased. Cancer and COVID registries, such as United Kingdom Coronavirus Cancer Monitoring Project (UKCCMP), COVID-19 and Cancer Consortium (CCC- 19) , and numerous studies were The meta-analysis was performed using the generic inverse-variance method with a random-effects model to calculate each outcome's risk. The calculated effect size was the OR and its 95% CI. The primary comparison were severe disease and death. All analyses were done using the Review Manager software, version 5.3 (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). The thresholds for statistical significance for overall effect tests were 0.05 and that for the tests of heterogeneity, within the overall, was 0.10. The I 2 coefficient was additionally used to quantify the degree of heterogeneity between the studies. After searching according to the criteria mentioned above, we assessed twenty articles with full text. Finally, we included sixteen studies for this meta-analysis. PRISMA diagram for the selection process of included studies is shown in Figure-1 . We assessed the quality of included studies by using NOS. Results for the quality assessment of included studies are shown in Table- 1. Two out of sixteen studies were prospectivecohort study. 11, 12 Remaining studies were retrospective. 7,13-25 Four thousand five hundred ten cancer patients were included and 53% of all patients (2421 patients) were male. Baseline characteristics of all included studies are shown in Table- 2. According to the analysis of univariable Figure 2c and 2d, respectively. In univariable analyses, immunotherapy within the last 30 days before COVID-19 diagnosis did not increase the risk of severe disease and death in cancer patients In univariable analyses, targeted therapies within the last 30 days before COVID-19 diagnosis did not increase the risk of severe disease and death in cancer patients There was heterogeneity between the included studies for death (p=0.08; I 2 =46%). In contrast, there was no heterogeneity between the included trials for severe disease (p=0.30; I 2 =16%). Forest plots of unadjusted ORs for the effect of targeted therapies on severe COVID-19 and risk of death from COVID-19 are shown in Figure 4a and 4b, respectively. In univariable analyses, cancer surgery within the last 30 days before COVID-19 diagnosis did not increase the risk of severe disease and death in cancer patients There was heterogeneity between the included studies for severe disease (p=0.06; ). In contrast, there was no heterogeneity between the included trials for death (p=0.24; I 2 =29%). Forest plots of unadjusted ORs for the effect of cancer surgery on severe COVID-19 and risk of death from COVID-19 are shown in Figure 5a and 5b, respectively. In univariable analyses, radiotherapy within the last 30 days before COVID-19 diagnosis did not increase cancer patients' risk of death (OR:0.82; 95% CI:0.50-1.37; p=0.46). There was no heterogeneity between the included trials (p=0.40; I 2 =0%). The J o u r n a l P r e -p r o o f forest plot of unadjusted ORs for the effect of radiotherapy on the risk of death from COVID-19 is shown in Figure 6 . In univariable analyses, cancer treatment within the last 30 days before COVID-19 diagnosis did not increase the risk of severe disease and death in cancer patients. Figure 7a and 7b, respectively. To the best of our knowledge, this was the first comprehensive meta-analysis regarding the effect of cancer treatment on the clinical course of COVID-19. In the present meta-analysis, we showed that active cancer treatment was not associated with an increased risk for severe disease and death from COVID-19. Furthermore, immunotherapy, targeted therapies, cancer surgery, and radiotherapy did not increase the risk of severe disease and death from COVID-19 in cancer patients. According to multivariable analyses, although there was no increased risk for severe disease and death from COVID-19, the risk of death from COVID-19 was higher in the cancer patients administered CT. On the other hand, the multivariable analysis did not show an increased risk for severe disease in this group of patients. During the COVID-19 pandemic, we learned that age and male sex are associated with higher severe disease and mortality rates. 26 thus, pulmonary and cardiac dysfunction. 32, 33 To make this robust and surge inflammatory response, individuals should have an effective immune system. However, the negative impact of CT on the immune system is well-known for years. 34 Furthermore, after the mitigation of immune functions by CT, recovery of the immune system might take a long time. 35 Targeted therapies have less risk for neutropenia or leukopenia than CT. 41 In this context, the immunocompromising effect of targeted agents is lower than CT. On the other hand, targeted therapies have various effects on the immune functions. They may enhance T cell immunity or suppress the immune system. 42 There has been no security concern regarding targeted agents in treating cancer patients during the pandemic. Furthermore, ESMO did not recommend the interruption of targeted therapies. 43 Our results were consistent with the previous expectations. Furthermore, we showed that showed that the postoperative complications and mortality risk were higher in the patients infected by SARS-Cov2 in the peri-operative setting. 52 In compliance with the concerns in this study's results, most elective surgical procedures were postponed across the world. However, articles published recently did not show increased mortality and severe disease risk in patients who had undergone elective surgery. 53, 54 Similarly, according to the results of the present meta-analysis, it seems that cancer surgery can be performed without increased risk for severe disease and death during the pandemic. During pandemic, authors and guidelines recommended the assessment of each patient for the risk and benefit of RT. They also recommended that hypofractionated regimens should be encouraged. Furthermore, active surveillance may be a good option in the low-risk prostate cancer patients. 55 The mitigation of patient admissions to the hospitals is the main purpose of all these recommendations. On the other hand, postponing elective surgeries during the pandemic increased the administration of CT and RT as well. 56 RT induced lymphopenia (RTIL) is the main concern for the use of RT during pandemic due to lymphopenia is the poor prognostic indicator for COVID-19. [57] [58] [59] Despite the lymphopenia effect of RT, stereotactic procedures can be used safely without an increased risk for RTIL. 60 Indeed, during the pandemic, stereotactic body RT (SBRT) is a good alternative for surgery. Furthermore, the authors recommended that RT can be performed safely during the pandemic. 61 In parallel to this recommendation, we did not show a safety concern regarding RT administration within the last 30 days before the COVID-19 diagnosis. We had some limitations in the present meta-analysis. First, fourteen out of sixteen studies included retrospective data. Only two trials assessed patients prospectively. WHO. WHO Coronavirus Disease (COVID-19) Dashboard Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System Survey of the Impact of COVID-19 on Oncologists' Decision Making in Cancer Managing cancer patients during the COVID-19 pandemic: An ESMO Interdisciplinary Expert Consensus Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyse COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan Determinants of COVID-19 disease severity in patients with cancer SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission Chemotherapy and COVID-19 Outcomes in Patients With Cancer Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study Serology-informed estimates of SARS-CoV-2 infection fatality risk in Sex differential in COVID-19 mortality varies markedly by age. The Lancet SARS-CoV-2 and COVID-19: A review of reviews considering implications for public health policy and practice Comorbidity and its Impact on Patients with COVID-19 Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study Covid-19 in Critically Ill Patients in the Seattle Region -Case Series The cytokine storm in COVID-19: An overview of the involvement of the chemokine/chemokine-receptor system The immune system and COVID-19: Friend or foe? Long term hematopoietic damage after chemotherapy and cytokine Significant impairment in immune recovery after cancer treatment COVID-19: consider cytokine storm syndromes and immunosuppression COVID-19 in Immunocompromised Hosts: What We Know So Far Immune dysfunction leads to mortality and organ injury in patients with COVID-19 in China: insights from ERS-COVID-19 study Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient Mortality within 30 days of receiving chemotherapy: a single regional experience from New Zealand The Risk of Neutropenia and Leukopenia in Advanced Non-Small Cell Lung Cancer Patients Treated With Erlotinib: A Prisma-Compliant Systematic Review and Meta-Analysis Targeted Therapy and Immunosuppression in the Tumor Microenvironment Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus Repurposing of Kinase Inhibitors for Treatment of COVID-19 Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion T-Cell Exhaustion in Chronic Infections: Reversing the State of Exhaustion and Reinvigorating Optimal Protective Immune Responses Changes in muscle, fat and bone mass after 36 weeks of maximal androgen blockade for prostate cancer Improving the Imaging Contrast of (68)Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties A systematic review: Role of systemic therapy on treatment and prevention of brain metastasis in renal cell carcinoma Pneumonitis from immune checkpoint inhibitors and COVID-19: current concern in cancer treatment Postoperative pulmonary complications Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study Outcomes of Elective Major Cancer Surgery During COVID 19 at Tata Memorial Centre: Implications for Cancer Care Policy Evaluating Postoperative Outcomes of Patients Undergoing Elective Procedures in an Ambulatory Surgery Center During the COVID-19 Pandemic Radiotherapy in the era of COVID-19 Shift in indications for radiotherapy during the COVID-19 pandemic? A review of organ-specific cancer management recommendations from multidisciplinary and surgical expert groups Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A systemic review and meta-analysis A systematic review of the influence of radiation-induced lymphopenia on survival outcomes in solid tumors Lymphocytopenia and Radiotherapy Treatment Volumes in the Time of COVID-19 Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer Cancer and COVID-19 -potentially deleterious effects of delaying radiotherapy Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy) Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study Outcomes of novel coronavirus disease 2019 (COVID-19) infection in 107 patients with cancer from Wuhan Determinants of COVID-19 disease severity in patients with cancer SARS-CoV-2 infection in cancer patients undergoing active treatment: analysis of clinical features and predictive factors for severe respiratory failure and death Cancer increases risk of in-hospital death from COVID-19 in persons <65 years and those not in complete remission Chemotherapy and COVID-19 Outcomes in Patients With Cancer Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. Cancer Discov High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study This manuscript is a meta-analysis and not required an ethical approval.All authors confirm that there is a dataset available when needed. There is no funding for this meta-analysis.J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f J o u r n a l P r e -p r o o f